Regenxbio [RGNX] Unchanged to Market Perform at SVB Leerink
SVB Leerink maintained its Regenxbio [RGNX] rating to the equivalent of Market Perform but changed the price target to $37 from $34, in a research note dated 2021-01-06. That figure represents around a -17.61% premium from where the company’s shares closed on Tuesday. In addition, RBC Capital Mkts launched coverage on May 13, 2020. The […]